In 2012, Colorado and Washington State legalized the commercial production and sale of cannabis for nonmedical use, and since then 22 other U.S. states have followed. The shift was viewed in many quarters as benign and overdue—involving an organic, even medicinal, intoxicant with no serious drawbacks. Advocates promised safe and accurately labeled products, reduced addiction to opioids, smaller prison populations, surging tax revenue, and a socially responsible industry that prioritized people over profits. But all of those promises have turned out to be overstated or simply wrong.  

Legalization has raised cannabis consumption dramatically, and also altered patterns of use. In the 1990s and early 2000s, most consumers smoked the drug and did so only occasionally or semi-regularly—say, on weekends with friends. Some people used more regularly, of course: In 2000, 2.5 million Americans reported daily or near-daily cannabis use. But by 2022, that had grown sevenfold to 17.7 million. Remarkably, that’s more than the 14.7 million who reported using alcohol that often. Today, more than 40 percent of Americans who use cannabis take it daily or near-daily, and these users consume perhaps 80 percent of all the cannabis sold in the U.S.

The drug’s potency has also risen sharply. Until the year 2000, the average potency of seized cannabis never exceeded 5 percent THC, the principal intoxicant in the plant. Today, smokeable buds, or flower, sold in licensed stores usually exceed 20 percent THC. Vapes, dabs, and shatter—all of which are forms of drug delivery that commercialization spread—are more potent still.

[Malcolm Ferguson: Marijuana is too strong now]

More frequent use of more potent products has led to a staggering rise in the typical consumer’s average weekly dose of THC. Back in the 1980s and ’90s, when potency averaged about 4 percent, someone consuming one 0.4-gram joint each weekend night—and none on weekdays—was averaging roughly 32 milligrams of THC a week. Average daily users today are consuming about 1.6 grams of high-potency flower a day, or its equivalent in other forms. That works out to more than 2,000 milligrams of THC a week—or about 70 times as much.

The numbers are shocking, and yet this is what happens when frequency, potency, and quantity all rise in tandem. For some consumers, high potency itself encourages more frequent use by delivering a stronger effect.

Medical science can’t yet clarify the effects of long-term use of 300-plus milligrams of THC a day, because this consumption pattern is new. Most controlled studies work with short-term exposure to smaller doses, often in the 20-to-50 milligram range, and observational studies that followed users for years were examining a drug—low-strength, infrequently used cannabis—that barely exists anymore.

But high-frequency use of high-potency marijuana raises a range of concerns. For one thing, there is little question that cannabis intoxication can impair cognitive functions including concentration and memory formation. That was not a big worry when most people used only on weekends. Daily use, however, means using on work and school days. The drug also impairs perception and motor control; the availability of strong, legal marijuana has been followed by increases in automobile crashes and emergency-room visits.

And over the long term, although some people can handle a wake-and-bake lifestyle, just like some alcoholic people are functional, there are likely millions of users for whom couch lock impedes career advancement, academic success, or meeting responsibilities to family.

On surveys, 63 percent of high-frequency users report enough cognitive, emotional, employment, and social problems as a result of using the drug to be coded as meeting the criteria for a cannabis-use disorder (a condition defined by being unable to fully control drug-use behavior despite its negative consequences). For technical reasons, we think that figure overstates the problem, but there is no doubt that the problem exists: 17 percent of high-frequency users report wanting cannabis so badly that there are times they can’t think of anything else. Chronic use may lead to other health problems as well. Most notably, evidence is mounting that frequent use of high-strength products raises the risk of serious mental illnesses such as schizophrenia.  

To be clear, these risks and harms do not remotely add up to a “cannabis crisis” in the same way that we speak of an opioid crisis or a meth crisis—calamities marked by widespread premature mortality and shattered families. Many people who enjoy cannabis have no trouble managing their use. They can now buy it cheaply and without stigma, in a variety of forms. And everyone can be relieved that adolescents’ cannabis use has stayed roughly where it was since legalization began. By one standard measure, use rose just 3 percent among 12-to-17-year-olds from 2012 to 2022.

But use has soared for adults (up 155 percent), especially for those 35 and older (up 300 percent), and the increase cannot be characterized as entirely benign. Many assumptions made about what would follow legalization seem naive in retrospect.

Those assumptions extended beyond the nature of the relationship between pot users and the drug, and how it might change. Soaring cannabis use would still have been a win, from public-health and crime-control perspectives, if it had resulted in less use of even more dangerous drugs. But it hasn’t. Predictions that cannabis legalization would reduce consumption of alcohol, a drug much more strongly associated with physical aggression, were not realized—reductions observed in some groups or contexts were offset by increases in others.  

Based on weak scientific evidence, many advocates likewise promised that legal cannabis would lead people to use fewer opioids. (Weedmaps—an online review site for pot—put up billboards all over the country promising reductions in opioid overdose, for instance.) Yet those early findings were reversed as more data became available, and recent reviews suggest that legalization is more likely to increase than reduce opioid-death rates. This should not be too surprising: Although the old “gateway drug” arguments of the 1970s and ’80s overstated the risk of merely trying marijuana, the commercialization of cannabis has clearly expanded high-frequency use, and dependence on any drug can increase the likelihood of using and developing dependence on other drugs.

[Read: Marijuana’s health effects are about to get a whole lot clearer]

Some promised criminal-justice benefits have also proved illusory, in part because advocates exaggerated the extent to which marijuana use entangled people in the criminal-justice system. “Discriminatory enforcement of marijuana laws is one reason that black and Latino Americans make up two-thirds of the U.S. prison population,” the progressive Center for American Progress noted in 2018, in a report advocating national legalization. But even before legalization, very few people were in prison for pot possession alone. There were a lot of pot-smoking burglars and robbers behind bars, but only about 2 percent of inmates were in prison solely for marijuana offenses, and most of those were traffickers or their employees.

That there had been too many marijuana-possession arrests is undoubtedly true. And legalization has cut them sharply, leaving mostly only arrests of underage users and of residual illegal suppliers. But even here, the case for outright legalization of supply was oversold: States that merely decriminalized marijuana possession saw declines almost as large. In California, for example, converting marijuana possession from a misdemeanor to a civil infraction reduced possession arrests by 86 percent in just 12 months. Subsequent legalization had only a modest incremental effect.

Allowing commercial supply—as opposed to merely decriminalizing possession—has produced other unintended consequences, though these consequences could easily have been anticipated because businesses typically follow the laws of economics.    

Large producers run by MBAs have adopted industrial agricultural practices that are brutally efficient, dramatically outcompeting the artisanal production that many advocates foresaw. Before legalization, much high-quality cannabis was grown in small indoor facilities; one 2006 Dutch study of 77 illegal grows reported an average size smaller than 200 square feet. Now an average-size commercial grow might operate on 10,000 to 20,000 square feet, and an industry magazine lists one producer (Copperstate Farms) as operating almost 2,000,000 square feet of greenhouse grow space; mixed-mode growers are even larger.

Commercial production has driven down prices, and so the cannabis tax windfall touted by many supporters of legalization has also been underwhelming. In California, cannabis excise and sales taxes peaked in 2021; by the first quarter of 2023, they were reported as accounting for only 0.2 percent of total state tax collections. Not all taxes due even get collected; in 2023, for instance, 15 percent of the state’s cannabis firms defaulted on taxes they owed.  

Falling prices have thinned profit margins, adding to the commercial imperative to expand the market and attract new customers. Hence the proliferation of edibles and other products that are more accessible to nonsmokers. The industry is targeting women—who historically used cannabis less than men did—as a growth demographic, just as the cigarette and alcohol industries had before. From 2012 to 2022, high-frequency use grew strongly for men (up 137 percent), but exploded among women (up 300 percent).

Many commercial cannabis providers have proved difficult to regulate. Initially, regulatory enforcement efforts tended to be modest, and that was an error. Misleading labels are commonplace in the cannabis industry today, and some producers use unapproved pesticides or exploitative labor arrangements.  

The 2018 Farm Bill created further opportunities for bad behavior. The bill was supposed to legalize nonintoxicating uses of the cannabis plant, such as growing fiber for clothes or seed for food and oil. Unfortunately, loopholes let unscrupulous actors sell intoxicating products completely outside of most states’ regulatory systems. The Farm Bill permits the production and sale of “hemp”—defined as any cannabis product containing less than 0.3 percent of delta-9 THC, the primary THC variant in cannabis. But edibles, being relatively heavy, can contain a lot of delta-9 THC and still, by weight, remain under the 0.3 percent threshold. What’s more, the marijuana plant contains nonintoxicating cannabinoids that can be chemically transformed into intoxicating cousins such as delta-8 THC. The resulting array of products, which can appeal to youth, may have no labeling requirements (depending on what state they’re being sold in) and no protection against unfamiliar and potentially dangerous synthetic by-products. They may not have been tested for pesticides either.

Unsurprisingly, hemp producers who do not follow product-safety rules have in many cases been outcompeting those state-licensed cannabis companies that try to follow the regulations, contributing to high cannabis-business failure rates and less reliable products for consumers.

These ills and others—the sprouting of cannabis shops on seemingly every block in some city neighborhoods, the smell of pot that greets many riders of public transportation—have not gone unnoticed by the American people. The election in November underscored the degree of disappointment with the results of marijuana legalization. Though Nebraska did become the 39th state to approve the drug for medical purposes, North and South Dakotans voted down ballot initiatives to legalize recreational use. Floridians did the same—despite $150 million in campaign spending by the industry and an endorsement from Donald Trump.

This pause in what had seemed an inexorable movement toward wider—and eventually national—legalization is healthy. Leaping all the way from prohibition to the enthusiastic embrace of a for-profit, freewheeling, corporate cannabis industry has clearly created downsides and excesses that legalization advocates did not initially imagine (or, in some cases, admit). States still considering legalization—and those that may be reconsidering how legalization has worked out for them so far—would be wise to instead explore the ample middle ground, or what the late drug-policy expert Mark Kleiman called a “grudging toleration” of legal use and supply. Even a society that otherwise embraces free-market capitalism should be open to middle paths for addiction-inducing intoxicants, which are not ordinary commodities.  

[Read: I don’t want to smell you get high]

What might grudging toleration look like in practice? In addition to eliminating the Farm Bill loopholes that have contributed to a Wild West environment in many places, we would offer four specific suggestions.   

1. Restrain the power of large-scale producers.

The cannabis supply chain spans growers, manufacturers who process and package the plant material, and retailers. Regulation is needed for farmers (concerning which pesticides are allowed, for instance) and retailers (testing compliance with laws blocking sale to minors, for example)—but the bigger challenges involve the manufacturers who produce the concentrated products, control the brands, and dominate marketing and advertising. Two remedies can help.

First, there is no reason to allow for-profit corporations to participate in product manufacturing. For-profit businesses are fabulously efficient at developing new products and driving up consumption. That’s fine when the product is cornflakes or canola, but not when it involves addictive drugs. Cannabis is an addiction-inducing intoxicant for which rapidly expanding consumption has significant costs.  

Instead, legalization could restrict cannabis-product manufacturing to nonprofits or public-benefit corporations. Reliance on nonprofits is a norm in some other industries providing goods or services that in one way or another involve issues beyond pure commerce. Most hospitals and universities, for instance, are either nonprofit or government-owned. In the cannabis industry, these organizations could be chartered to undercut illegal supply by producing to meet existing demand, without promoting greater consumption.

Second, especially in places where for-profit manufacturers are still permitted, major manufacturers should be barred from owning, operating, or controlling either farms or retail outlets. Similar restrictions were part of many states’ plans when alcohol prohibition was repealed, and they might limit big corporations’ power—including their lobbying power. Likewise, they should be barred from merging with tobacco and alcohol companies.

2. Curtail high-potency products.

For many, the purpose of legalization was to replace the illegal market with legal, regulated supply. But legalization has also changed the market, bringing in a slew of more potent products. Drug-reform advocates sometimes invoke the so-called iron law of prohibition, which claims that prohibition begets more potent forms (because, being more compact, they are more easily hidden). But with cannabis, the opposite happened: It was legalization that spread higher-potency forms of the drug.  

Whether cheap, higher-potency products necessarily exacerbate health harms is much debated. But history is replete with examples of inexpensive, high-potency forms of drugs creating new problems, from the British Gin Craze of the first half of the 18th century in London (during which consumption increased eightfold to about one gallon per person per year) to the current fentanyl epidemic, which has killed more Americans than heroin ever did.

Some fear that banning higher-potency products will create or greatly expand illegal markets, but modern societies often ban certain forms of a product without creating big illegal markets—as long as other forms remain legal. For instance, throughout much of the 20th century, many countries banned the sale of absinthe, but there was no big illegal market for absinthe because other liquors were available. Likewise, today’s bans on caffeinated alcoholic drinks and flavored cigarettes are mostly honored.

Quebec already essentially bans dabs, butane hash oil, and other high-potency products, and it has considerably less cannabis use than other provinces of Canada.    

The U.S. should likewise ban such products, and maybe also the synthesis of artificial cannabinoids. And for products that stay within the potency limit, a further safeguard could be taxing more potent products at a higher rate, just as is done with alcoholic beverages.

3. Leave room for small-scale producers and other small businesses.

The primary challenge to public health does not come from the many small artisanal producers of marijuana, or from retailers. The greater problem is Big Marijuana. Applying the same rules to all parties burdens hobbyists and boutique producers while letting corporations run amok.

Most states have enacted cottage-food-production laws that exempt small-scale producers of craft-food products (baked goods, pickles, honey, etc.) from the strict scrutiny that is appropriate for agribusiness and food conglomerates. Cannabis policy could make similar distinctions.  

Small growers might be exempted from certain regulations when selling only flower—and also prohibited from selling refined or dangerous products, just as cottage-food producers are usually banned from selling meats or goods that need to be refrigerated.

4. Get public safety and public health off the sidelines.

In order to limit the damage done by legal addictive products, society needs effective public-health regulation. And in order to thrive, licensed legal industries need government enforcement against illegal suppliers. Both of these necessities have been lacking.

Neither regulators nor police have attacked illegal production, promotion, and sale with sufficient vigor, perhaps because any enforcement involving marijuana has become entangled—at least in the minds of many progressives—with concerns about the carceral state, or anti-police sentiment more generally.

[Jane C. Hu: Almost no one is happy with legal weed]

But when the legal risk of, say, operating an unlicensed weed shop drops to near-zero, the illegal industry grows and the legal industry suffers, undermining the legalization regime and tax revenue at the same time. Enforcement agencies, those who oversee them, and the activist community need to shake off the misperception that enforcing the rules of a legal industry is a revival of the War on Drugs.

Similarly, public-health departments must start informing the public more vigorously about the health risks of cannabis, just as they do those of tobacco, alcohol, and gambling. Thus far, they have generally failed to do this, perhaps because of misplaced fears of reenacting hysterias of prior eras. Today, a big, legal industry is selling a product with established health risks, and public health needs to embrace its traditional role as an advocate for health over profit.  

These and other reforms would better balance the trade-offs between profit and public interest. Naturally, the industry will fight them, but this should only increase urgency. Naive and self-serving advocates shaped (and, via the initiative process, sometimes wrote) many state-level legalization bills, with results that should trouble us. Legalization should be redesigned where it already exists, and efforts to expand it to other states or nationally should learn from the mistakes of the recent past.

This is an edition of The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the best in culture. Sign up for it here.

Americans keeping close track of political news may have been toggling their screens today between Senate confirmation hearings: the second day of Robert F. Kennedy Jr.’s for secretary of Health and Human Services, and the first for Tulsi Gabbard’s for director of national intelligence and Kash Patel’s for FBI director. But each of those three hearings deserves the public’s full attention: Donald Trump’s nominees offered new glimpses into their approaches to policy, truth, and loyalty to the president.

Robert F. Kennedy Jr., Day Two

Ahead of Kennedy’s first day of hearings, our colleague Nicholas Florko noted that the HHS nominee is no stranger to conspiracist statements: “RFK Jr. has insinuated that an attempt to assassinate members of Congress via anthrax-laced mail in 2001 may have been a ‘false flag’ attack orchestrated by ‘someone in our government’ to gin up interest in the government preparing for potential biological weapon threats. He has claimed that COVID was ‘targeted to attack Caucasians and Black people,’ and that 5G is being used to ‘harvest our data and control our behavior.’ He has suggested that the use of antidepressants might be linked to mass shootings.”

“If Republican senators skirt around [Kennedy’s] falsehoods during today’s confirmation hearings,” Nicholas wrote, “it will be evidence of their prevailing capitulation to Trump. And it also may be a function of Kennedy’s rhetorical sleights … He’s capable of rattling off vaccine studies with the fluency of a virologist, which boosts his credibility, even though he’s freely misrepresenting reality.” But Kennedy’s sleights didn’t serve him quite as well today as he might have hoped.

At several points, senators encouraged Kennedy to acknowledge that vaccines are not the cause of autism, but instead of confirming what numerous studies have shown to be true, Kennedy insisted that he would need to “look at all the data” before coming to any conclusions. “The room went silent today during Senator [Bill] Cassidy’s closing questions,” Nicholas noted when we spoke this afternoon. “Cassidy was practically begging Kennedy to recant his previous statements on vaccines. Kennedy, like everyone else in the room, had to know this was a make-or-break moment for his confirmation. But despite the potential fallout, Kennedy refused, promising only that he would look at any studies presented to him disproving a link between vaccines and autism.”

The nominee for HHS secretary also showed, for the second day in a row, his lack of understanding about basics of the Medicare system, fumbling his answers to a series of rapid-fire questions from Senator Maggie Hassan, a Democrat from New Hampshire. Hassan also shared that she is the mother of a 36-year-old with cerebral palsy, and accused Kennedy of relitigating settled science on the fact that vaccines do not cause autism. “It’s the relitigating and rehashing and continuing to sow doubt so we can’t move forward, and it freezes us in place,” she argued.

Cassidy, whose vote could prove key to whether RFK Jr. is confirmed, said after today’s hearing that he is “struggling” over whether to confirm Kennedy.

Tulsi Gabbard

Gabbard came into her confirmation process with a history that raises questions about her commitment to national security (she has, among other things, met with former Syrian President Bashar al-Assad and expressed sympathetic views toward Russian President Vladimir Putin). As our colleague Tom Nichols wrote in November, “Gabbard has every right to her personal views, however inscrutable they may be. As a private citizen, she can apologize for Assad and Putin to her heart’s content. But as a security risk, Gabbard is a walking Christmas tree of warning lights. If she is nominated to be America’s top intelligence officer, that’s everyone’s business.”

The topic that ultimately received much attention in her confirmation hearing today was her refusal to say whether Edward Snowden is a traitor. Despite pressure from Democratic and Republican senators, Gabbard refused to answer the question, repeating that Snowden had broken the law and that she would take steps to make sure whistleblowers know how to properly make a complaint. Gabbard also revealed that she was unable to extract any concessions in her 2017 meeting with Assad. “I didn’t expect to,” she said.

Gabbard’s potential confirmation will depend on how her somewhat incoherent set of policy views sits with Republican senators. Last week, our colleague Elaine Godfrey explored the one through line—besides ambition—that has guided Gabbard’s otherwise inconsistent political career.

Kash Patel

Donald Trump is not always clear about what he means when he refers to “DEI,” but presumably it involves how someone’s identity is taken into consideration during the hiring process. In this morning’s press conference addressing the tragic plane crash last night, Trump asserted, without evidence but crediting his “common sense,” that DEI hiring at the Federal Aviation Administration was at fault.

It was odd, then, that a few hours later, Republican senators used Patel’s confirmation hearing to highlight his identity: Senator Lindsey Graham of South Carolina asked about examples of racism Patel has experienced, and Senator Mike Lee of Utah acknowledged the struggles Patel and his father must have faced as racial minorities in the United States and Uganda, respectively. Senator Thom Tillis of North Carolina, as if he were reading from a book report about the Gujarati people, lauded the religious diversity in Gujarat, India, where Patel’s family is originally from, omitting the state’s extreme tensions and violent history. Patel opened his own remarks by acknowledging his family’s journey from abroad. He invoked the phrase Jai Shri Krishna, a standard greeting for a sect of Hindus seeking blessings.

Patel was calm and still—he became riled up only when questioned by Senator Amy Klobuchar about his past suggestion that he would “shut down the FBI Hoover Building on day one and reopen it the next day as a museum of the ‘deep state.’” But he was walking a tightrope. Today’s hearing may be the rare instance when Patel has publicly broken with Trump, to whom he has otherwise been unequivocally loyal. He refused to explicitly state that Trump lost the 2020 election, but he also said, “I do not agree with the commutation of any sentence of any individual who committed violence against law enforcement.”

Overall, Patel seemed to be trying to carefully toe a line, answering questions about the culture-war issues that Trump and congressional Republicans care about—Senator Marsha Blackburn, for example, asserted during the hearing that the FBI prioritizes DEI and “counting Swiftie bracelets” over conducting investigations—while attempting not to alienate the employees he hopes to lead. Pressed by Blackburn, Patel made a vague statement about the “high standards” FBI employees must meet.

Related:

RFK Jr. has a lot to learn about Medicaid. What everyone gets wrong about Tulsi Gabbard

Here are four new stories from The Atlantic:

The memo that shocked the White House The near misses at airports have been telling us something. Donald Trump is just watching this crisis unfold. Jonathan Lemire: “What I saw at Trump’s first press conference”

Today’s News

Officials announced that there are no survivors in the crash last night between a U.S.-military Black Hawk helicopter and a regional American Airlines passenger jet landing at an airport near Washington, D.C. Three soldiers were aboard the helicopter, and 64 people were on the flight from Wichita, Kansas. Donald Trump appointed Christopher Rocheleau as the acting administrator of the Federal Aviation Administration. The agency had not had an administrator since the start of Trump’s new term. Eight hostages were released from Gaza by Hamas, and Israel released 110 Palestinian prisoners.

Dispatches

Time-Travel Thursdays: Don Peck interviews Nicholas Carr about h​​ow online life has rewired our brains.

Explore all of our newsletters here.

More From The Atlantic

“The ‘exciting business opportunity’ that ruined our lives” Trump’s war on meritocracy If Iranian assassins kill them, it will be Trump’s fault, Tom Nichols writes. Don’t politicize aviation safety. The return of snake oil Why Meta is paying $25 million to settle a Trump lawsuit

Evening Read

Illustration by Ben Kothe / The Atlantic. Source: Getty.

Your FOMO Is Trying to Tell You Something

By Faith Hill

I feel deeply haunted by the thought that if I don’t go to the party or the dinner or the coffee stroll, my one wild and precious life will be void of a joyful, transformative event—one I’d surely still be thinking about on my deathbed, a friend at my side tenderly holding my hand and whispering, Remember? That time we went bowling and the guy in the next lane over said that funny thing? Every year, my New Year’s resolution is to keep one night of the week free from social plans. Almost every week, I fail.

Read the full article.

Culture Break

Illustration by The Atlantic. Source: Jamie McCarthy / Getty.

Listen. In the latest episode of Radio Atlantic, the MSNBC host Chris Hayes speaks with Hanna Rosin about how bad the war for your attention has really gotten.

Read. The Stranger Things effect is coming for the novel, Mark Athitakis writes.

Play our daily crossword.

Stephanie Bai contributed to this newsletter.

When you buy a book using a link in this newsletter, we receive a commission. Thank you for supporting The Atlantic.